A double blind trial of a new topical steroid formulation containing desoximetasone against fluocinolonacetonid cream.
A randomized double-blind left-right comparative trial was carried out between a new steroid Desoximetason 0,25% (Ibaril) and fluocinolone acetonide 0,025% cream. Evaluation of symptoms on 50 patients suffering from endogenous eczema was recorded after 1, 2, 3 and 4 weeks. There was a significantly better effect of Ibaril compared to Fluocinolone-acetonide as judged by the observer during the 1st, 3rd and 4th week of treatment. After the 2nd week treatment Ibaril showed a better effect, however, a significancy could not be established.
D002986:Clinical Trials as Topic; D003877:Dermatitis, Contact / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D003907:Dexamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy; D005446:Fluocinolone Acetonide / Q000627:therapeutic use*; D006801:Humans
D005446:Fluocinolone Acetonide; D003907:Dexamethasone